Literature DB >> 8766967

[Dichloromethylenbiphosphonic acid in the therapy of myositis ossificans progressive (MOP)].

M G Alpigiani1, M G Puleo, L Callegarini, E Di Bella, C Debbia, C Buzzanca, A Iester.   

Abstract

The authors report 3 cases of myositis ossificans progressiva (MOP) treated with i.v. dichloromethylenbiphosphonic acid. Two of these patients presented a severe development of the disease so that they could not walk anymore. After a few months of treatment with dichloromethylenbiphosphonic acid (300 mg/die for 10 continual days every month) sufficient recovery in motor capacity was achieved that walking was possible again. The favourable effect of therapy has been shown only by clinical features because there is no biological marker to monitor in the follow-up. During the treatment no side effect or modification of the markers of liver and kidney activity was observed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8766967

Source DB:  PubMed          Journal:  Minerva Pediatr        ISSN: 0026-4946            Impact factor:   1.312


  2 in total

1.  An unusual cause of pulmonary hypertension and right heart failure.

Authors:  S Orme; J C Underwood; E McCloskey; T J Hendra
Journal:  Postgrad Med J       Date:  1998-11       Impact factor: 2.401

2.  MYOSITIS OSSIFICANS PROGRESSIVA: CASE REPORT.

Authors:  Frederico Barra de Moraes; Alano Ribeiro de Queiroz Filho; Leonardo Jorge da Silva; Válney Luiz da Rocha; Nayara Portilho Araújo; Ernesto Quaresma Mendonça; Érica Paiva de Almeida
Journal:  Rev Bras Ortop       Date:  2015-12-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.